{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/mash-trial-design#webpage",
"url": "https://www.fortrea.com/insights/mash-trial-design",
"name": "MASH trial design",
"description": "Explore this Fortrea white paper examining clinical development strategies for liver cirrhosis secondary to NASH and the evolving approaches being used to support successful therapeutic development in this complex patient population. The white paper explores biomarker-based patient identification strategies, target population selection, disease progression assessment, and key trial design considerations that influence the development of therapies for NASH-related cirrhosis. It provides detailed insight into the role of biomarkers in identifying appropriate patients for clinical research, the importance of defining target populations, and the challenges associated with designing studies capable of generating meaningful clinical evidence. The paper also evaluates surrogate endpoints and clinical outcome endpoints used in NASH cirrhosis clinical trials while discussing development pathways, efficacy assessments, and regulatory considerations that can help sponsors optimize study design, improve trial execution, and advance liver cirrhosis drug development programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "MASH trial design",
"item": "https://www.fortrea.com/insights/mash-trial-design"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/mash-trial-design#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/mash-trial-design#webpage"
},
"headline": "Clinical Development Strategies for Liver Cirrhosis Secondary to NASH: Biomarkers, Target Populations, and Endpoint Selection | Fortrea White Paper",
"description": "Explore this Fortrea white paper examining clinical development strategies for liver cirrhosis secondary to NASH and the evolving approaches being used to support successful therapeutic development in this complex patient population. The white paper explores biomarker-based patient identification strategies, target population selection, disease progression assessment, and key trial design considerations that influence the development of therapies for NASH-related cirrhosis. It provides detailed insight into the role of biomarkers in identifying appropriate patients for clinical research, the importance of defining target populations, and the challenges associated with designing studies capable of generating meaningful clinical evidence. The paper also evaluates surrogate endpoints and clinical outcome endpoints used in NASH cirrhosis clinical trials while discussing development pathways, efficacy assessments, and regulatory considerations that can help sponsors optimize study design, improve trial execution, and advance liver cirrhosis drug development programs.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2024-10/GettyImages-643324844.webp"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2024-10-15",
"dateModified": "2024-10-15",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2024-10/WP_0028_CDCS_Trial%20Design%20Liver%20Cirrhosis%20NASH_0823_v3.pdf",
"encodingFormat": "application/pdf"
}
}
]
}